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Abstract
Background: As HIV-infected infants have high mortality, the World Health Organization now recommends
initiating antiretroviral therapy as early as possible in the first year of life. However, in many settings, laboratory
diagnosis of HIV in infants is not readily available. We aimed to develop a clinical algorithm for HIV presumptive
diagnosis in infants < 10 weeks old using screening data from the Children with HIV Early Antiretroviral therapy
(CHER) study in South Africa.
HIV-infected and HIV-uninfected exposed infants < 10 weeks of age were identified through Vertical Transmission
Prevention programs. Clinical and laboratory data were systematically recorded, groups were compared using
Kruskal-Wallis, analysis of variance (ANOVA), and Fisher’s exact tests. Receiver Operating Characteristic (ROC) curves
were compiled using combinations of clinical findings.
Results: 417 HIV-infected and 125 HIV-exposed, uninfected infants, median age 46 days (IQR 38-55), were included.
The median CD4 percentage in HIV-infected infants was 34 (IQR 28-41)%. HIV-infected infants had lower weight-
for-age, more lymphadenopathy, oral thrush, and hepatomegaly than exposed uninfected infants (Adjusted Odds
Ratio 0.51, 8.8, 5.6 and 23.5 respectively; p < 0.001 for all). Sensitivity of individual signs was low (< 20%) but
specificity high (98-100%). If any one of oral thrush, hepatomegaly, splenomegaly, lymphadenopathy, diaper
dermatitis, weight < 50
th centile are present, sensitivity for HIV infection amongst HIV-exposed infants was 86%.
These algorithms performed similarly when used to predict severe immune suppression.
Conclusions: A combination of physical findings is helpful in identifying infants most likely to be HIV-infected. This
may inform management algorithms and provide guidance for focused laboratory testing in some settings, and
should be further validated in these settings and elsewhere.
Background
Identifying HIV infection in early infancy is an impor-
tant challenge to effective paediatric HIV care and treat-
ment. HIV-infected infants have a high mortality,
particularly in heavily disease-burdened settings [1-6].
The Children with HIV Early Antiretroviral Therapy
(CHER) trial [4] recently showed that early antiretroviral
therapy (ART), commenced at a median of 7 weeks of
age was associated with a 75% reduction in mortality
versus the prevailing standard of care at the time (the
WHO 2006 guidelines) [7]. Importantly, most deaths
occurred in the first few months of life and none of the
infants had a CD4 < 25% or advanced HIV disease
according to Centers for Diseases Control criteria [4].
Diagnostic HIV-1 DNA PCR is recommended at 6
weeks of age in HIV-exposed infants going through Ver-
tical Transmission Prevention (VTP) programs [8].
Although qualitative HIV-1 PCR testing is becoming
more available, turn-around time for results and subse-
quent initiation of ART can take weeks. Clinical algo-
rithms for HIV diagnosis in young infants could be
useful for identifying those with probable HIV infection
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Clinical algorithms for pediatric HIV diagnosis [9-13]
have been developed but very few have used data on
clinical manifestations from very young infants. To our
knowledge, only one algorithm for this age group has
been developed in Zimbabwe [9], using data from the
pre-VTP era. Our aim was to investigate the predictive
value of clinical characteristics for HIV infection in
HIV-infected and HIV-exposed uninfected infants and
to develop a clinical algorithm for identification of HIV
infection in young infants who have failed VTP
interventions.
Methods
Participants, data collection and laboratory methods
Data were collected during the screening phase of two
clinical trials between 2005 to 2007 in Cape Town and
Soweto, South Africa; the CHER trial, and a parallel
observational cohort study. For randomization in the
CHER study, baseline CD4 had to be ≥ 25% [4]. A small
number of infants with lower CD4 percentage were
enrolled in the parallel observation cohort, so were
included in the present analysis. Infants were identified
through VTP and referred to the study sites. VTP con-
sisted of single dose nevirapine (NVP) to mother and
newborn; and in Cape Town, Zidovudine (ZDV) was
given to mothers from 32 weeks gestation, and to the
infant for one week. HIV-exposed infants were tested by
HIV-1 DNA PCR (Roche Amplicor HIV-1 DNA assay
version 1.5, Roche Molecular Systems, Inc., Branchburg,
NJ) between 4 and 10 weeks of age. At screening, clini-
cal signs were recorded and HIV infection was con-
firmed by plasma HIV RNA level > 5000 copies per ml
(Roche Ampliprep/Cobas Amplicor assay, Roche Mole-
cular Systems, Inc., Branchburg, NJ) (see below). High
viral loads were not titrated beyond 750,000 viral
copies/mL (log 5.88). HIV-exposed infants testing HIV-1
DNA PCR negative were still eligible for the cohort
study, and were included in this analysis. HIV-infected
infants had lymphocyte subsets measured using Beck-
man Coulter single platform lyse-no wash procedure
using Immunoprep™ reagents with Flow Count™
fluorospheres. A small number of HIV-infected infants
with CD4% below 25% were eligible for the concurrent
cohort study and were therefore included in the analysis.
Data from screening for both studies were collected
on predefined questionnaires by doctors aware of the
infants’ HIV status, but unaware of their degree of
immunosupression. Reflux was defined as excessive
vomiting after feeds. Hepatomegaly was defined as a
palpable liver > 1 cm below the costal margin in the
right mid-clavicular line. Splenomegaly was noted if the
spleen was palpable. Encephalopathy was defined as
symmetrically abnormal neurological examination,
microcephaly or lack of head circumference growth, or
cerebral atrophy on CT scan. Lymphadenopathy was
defined as palpable lymph nodes greater than 1 cm in
diameter. Lymphadenopathy was generalised if it was
palpable in two or more areas including cervical, axil-
lary, or inguinal regions. Diaper dermatitis was an
abnormal rash of any type in the diaper area, candidal
or otherwise. Standard World Health Organisation
growth curves (available at http://www.who.int/child-
growth/standards/en/) were used to define cut-off values
for 3
rd,1 5
th,a n d5 0
th centiles (marked on the charts)
for weight-for-age. Anemia and neutropenia were
defined according to the Division of AIDS toxicity table
for grading severity of Pediatric (≤ 3m o n t h so fa g e )
adverse experiences (available at http://rsc.tech-res.com/
safetyandpharmacovigilance/gradingtables.aspx)
Statistical methods
Stata version 9.0 (College Station, Texas) was used for
analysis. Screening data were compared using Kruskal-
Wallis tests, analysis of variance (ANOVA), and Fisher’s
exact tests. Similar analysis was performed for CD4%
data. Multivariate regression was performed including
age as a dependent variable to determine the relation-
ship between log viral load and clinical findings. We
estimated sensitivity, specificity, positive likelihood
ratios, and age-adjusted odds ratios (OR), for the asso-
ciation between HIV status and clinical parameters. The
95% confidence intervals (CI) were calculated using
standard methods. Receiver Operating Characteristic
(ROC) curves were examined using combinations of
clinical predictors of HIV infection. Characteristics with
significant age-adjusted OR in univariate analyses (p <
0.05) were combined to achieve the highest Area Under
the Curve (AUC) for the ROC.
Ethical Considerations
The Ethics Committees of the Universities of Stellen-
bosch and Witwatersrand approved the studies. Written
informed consent was obtained from legal guardians of
all infants.
Results
417 HIV-infected and 125 HIV-exposed, uninfected
(HEU) infants were included. The median age at screen-
ing was 46 days (Interquartile range, [IQR] 38-55). The
median CD4% of the HIV-infected infants was 34%
(IQR 28-41). Sixty-two HIV-infected infants with CD4 <
25% were included in the analysis.
Only 12% of infants were ever breastfed; uptake of
VTP was 90%. The demographics and prevalence of
selected clinical characteristics of infants by infection
status at screening are shown in Table 1. Weight-for-
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in HIV-exposed uninfected infants. Infected infants were
m o r el i k e l yt oh a v ew e i g h tb e l o wt h e3
rd and 15
th but
not the 50
th centile. Lymphadenopathy (axillary, cervical,
generalised, or any), oral thrush, splenomegaly, or hepa-
tomegaly and a history of reflux were more common in
infected infants. Diaper dermatitis (candidal, atopic, or
other) was also significantly associated with HIV status.
Both anemia and neutropenia of grade 2 or above were
almost exclusively found in HIV-infected infants. Elec-
trolyte and liver function test results did not differ
between the groups (data not shown). However, 27% of
HIV-infected infants had weight above the 50
th centile.
The 62 HIV-infected infants with CD4% < 25 had a
median age of 51.5 days [IQR 42-66]. Their median
CD4% was 20.9 [IQR 17.6-23.3]. Compared with those
with CD4 ≥ 25%, severely immunocompromised infants
were older and more likely to have weight below 3
rd
and 15
th centile for age, but not 50
th (Table 2). Severely
immunosuppressed infants were also more likely to have
lymphadenopathy, hepatomegaly, splenomegaly, and a
history of gastroenteritis or pneumonia.
The median log viral load of the HIV-infected infants
w a s5 . 8 8[ R a n g e3 . 7 8 - 5 . 8 8 ] .I nau n i v a r i a t er e g r e s s i o n
model, there was weak association between log viral
load and age (regression coefficient 2.77; 95% CI -0.53 -
6.06). No age-adjusted clinical finding or event was pre-
dictive of higher viral load except oral thrush (regression
coefficient 0.09, 95% CI 0.02; 0.16).
The sensitivity, specificity, and positive likelihood ratio
(LR+) of selected findings for HIV infection is shown in
Table 3. Low weight-for-age, any lymphadenopathy,
hepatomegaly, splenomegaly, oral thrush, and reflux
were all highly specific but insensitive for HIV infection.
Table 1 Frequency of selected physical findings and clinical events in very young HIV-infected and exposed
uninfected infants.
Exposed uninfected n = 125 Infected
n = 417
Unadjusted p-value
3 Adjusted Odds Ratio (95% CI)
3
Female gender (%)
Median age, days (IQR)
57 (46)
48 (38-51)
239 (57)
45 (38-56)
0.18
0.07
1
Anthropometry at screening
Median weight, kg (IQR) 4.8 (4.3-5.2) 4.4 (3.9-4.9) < 0.001
2 0.51 (0.38-0.68)
Weight < 3
rd centile (%) 8 (6.4) 79 (18.9) < 0.001 3.2 (1.4-6.8)
Weight < 15
th centile (%) 23 (18.4) 166 (39.8) < 0.001 2.8 (1.7-4.6)
Weight < 50
th centile (%) 79 (63.2) 303 (72.7) 0.04 1.5 (0.98-2.3)
Median length, cm 55 (53-56) 54 (52-56) 0.78
2 0.97 (0.91-1.04)
Median HC, cm 39 (38.4-40) 39 (38-40) 0.20
2 0.95 (0.88-1.03)
Physical exam findings at screening
Any LAD
# (%) 6 (5) 132 (32) < 0.001 8.8 (3.8-20.9)
Candidal rash (%) 8 (6) 46 (11) 0.17 1.6 (0.8-3.6)
Atopic dermatitis (%) 13 (10) 83 (20) 0.01 2.0 (1.1-3.7)
Diaper dermatitis 23 (18) 149 (36) < 0.001 2.4 (1.5-4.0)
Oral thrush (%) 13 (10) 163 (39) < 0.001 5.6 (3.0-10.2)
Hepatomegaly (%) 1 (1) 70 (17) < 0.001 23.5 (3.2-170.8)
Splenomegaly (%) 0 (0) 30 (7) < 0.001 *
Clinical event prior to or at screening
Gastroenteritis (%) 8 (6) 44 (11) 0.17 1.7 (0.8-3.7)
Otitis media (%) 4 (3) 6 (1) 0.20 0.4 (0.1-1.5)
Sepsis (%) 3 (2) 12 (3) 1.00 1.0 (0.3-3.7)
URTI (%) 24 (19) 81 (19) 1.00 1.0 (0.6-1.7)
Reflux (%) 0 (0) 15 (4) 0.03 *
Pneumonia (%) 7 (6) 29 (7) 0.67 1.2 (0.5-2.8)
Laboratory findings
Anemia (%) 0 (0) 22 (5) 0.004 *
Neutropenia (%) 0 (0) 15 (4) 0.03 *
1 Kruskal Wallis
2ANOVA
3Fishers exact unless otherwise specified
3Age-adjusted OR of infected infants versus HIV exposed-uninfected infants
IQR - Interquartile range. CI - Confidence Interval. HC - Head circumference. URTI - Upper respiratory tract infection.
#Any lymphadenopathy - includes generalized, cervical, axillary or inguinal
*Small sample sizes prevented the calculation of adjusted OR
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th centile, as
in the algorithm by Iliff et al [9] improved sensitivity
and specificity.
A combination of various clinical findings in a ROC
improved sensitivity without compromising specificity
(Table 4). For example, if any one of six clinical findings
- oral thrush, hepatomegaly, splenomegaly, lymphadeno-
pathy, diaper dermatitis, or weight below the 15
th centile
were present, the sensitivity for HIV infection amongst
HIV-exposed infants was 78% and the specificity 62%.
Increasing the weight cut-off to < 50
th centile improved
sensitivity to 89% (Table 4). By excluding diaper derma-
titis, including reflux, and changing the weight cut-off to
below the 3
rd centile, specificity increased to 80% but
sensitivity decreased to 64%. When cut-offs to any two
findings were increased, specificity approached 100%,
but compromised sensitivity. Although nurses can be
trained to recognise hepatosplenomegaly and lymphade-
nopathy, simple algorithms may be preferred by
programs with high-volume or nurse-run programs.
Table 4 shows simplified algorithms including only dia-
per dermatitis, oral thrush, and weight < 3
rd and 50
th
centiles, giving sensitivities ranging from 61 to as high
as 85%, with that for 15
th centile falling somewhere in
between (data not shown).
When these algorithms were applied to HIV-infected
infants to predict severe immune suppression (CD4 <
25%), the algorithms were sensitive, but poorly specific
using one cut-off finding. For example, any one of the
six clinical findings in Table 4B (weight below 50
th cen-
tile, hepatomegaly, splenomegaly, diaper dermatitis, and
lymphadenopathy) had a sensitivity of 89% but specifi-
city of 2% for predicting severe immune suppression.
Discussion
We found that certain clinical signs and symptoms are
highly specific for HIV infection in relatively healthy
infants exposed to ARVs for prevention of vertical
Table 2 Frequency of selected physical findings and clinical events in very young HIV-infected with CD4% < 25%
(severe immune suppression) versus CD4 ≥ 25%
CD4 < 25% n = 62 CD4 ≥ 25% n = 313 Unadjusted p-value
3 AOR (95% CI)
3
Female gender (%) 29 (46.8) 187 (59.7) 0.06
Median age, days (IQR) 52 (42-66) 45 (39-55) 0.002
1
Anthropometry at screening
Median weight, kg (IQR) 4.3 (3.9-5) 4.4 (4.0-4.9) 0.228 1.6 (1.1-2.4)
Weight < 3
rd centile (%) 19 (30.6) 52 (16.6) 0.010 NA
Weight < 15
th centile (%) 36 (56.4) 115 (37.0) 0.004 NA
Weight < 50
th centile (%) 51 (82) 228 (72.8) 0.121 NA
Median length, cm 54 (52.5-55) 54 (52-56) 0.563 1.1 (0.98-1.2)
Median HC, cm 39 (38-40) 39 (38-40) 0.859 1.1 (0.9-1.1)
Physical exam findings at screening
Any LAD
# (%) 33 (53.2) 93 (29.7) < 0.001 0.4 (0.2-0.7)
Atopic dermatitis (%) 14 (22.6) 64 (20.4) 0.705 1.1 (0.5-2.1)
Diaper dermatitis 28 (45.2) 111 (35.5) 0.149 0.7 (0.4-1.2)
Oral thrush (%) 29 (46.8) 115 (36.7) 0.138 0.7 (0.4-1.1)
Hepatomegaly (%) 11 (17.7) 19 (6.1) 0.002 0.4 (0.2-0.8)
Splenomegaly (%) 19 (30.6) 51 (16.3) 0.008 0.5 (0.3-0.9)
Clinical event prior to or at screening
Gastroenteritis (%) 12 (19.4) 29 (9.3) 0.020 0.5 (0.2-1.0)
Otitis media (%) 1 (1.6) 5 (1.6) 0.993 1.5 (0.2-13.8)
Sepsis (%) 4 (6.5) 7 (2.2) 0.072 0.4 (0.1-1.5)
URTI (%) 11 (17.7) 65 (20.8) 0.558 1.2 (0.6-2.5)
Reflux (%) 3 (4.8) 11 (35.1) 0.615 0.6 (0.2-2.4)
Pneumonia (%) 11 (17.2) 17 (5.4) 0.001 0.2 (0.1-0.6)
Laboratory findings
Anemia (%) 4 (6.5) 18 (5.8) 0.830 1.0 (0.3-3.0)
Neutropenia (%) 4 (6.5) 9 (2.9) 0.160 0.4 (0.1-1.2)
1 Kruskal Wallis
2ANOVA
3Fishers exact unless otherwise specified
3Age-adjusted OR of HIV-infected infants with CD4 ≥ 25% versus those with CD4 < 24%
IQR - Interquartile range. CI - Confidence Interval. HC - Head circumference. URTI - Upper respiratory tract infection.
#Any lymphadenopathy - includes generalized, cervical, axillary or inguinal
*Small sample sizes prevented the calculation of adjusted OR
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Page 4 of 7transmission below 10 weeks of age. Any one of a com-
plex of findings including oral thrush, lymphadenopathy,
hepatomegaly, splenomegaly, weight centile, diaper der-
matitis, or reflux, give specificities and sensitivities of up
to 89% and 80% respectively. A small number of studies
prospectively investigated clinical symptoms in acutely
infected infants during breastfeeding. In a study by
R o u e te ta li nC o t ed ’Ivoire, 22 of 342 infants developed
postnatal HIV infection. Acute retroviral syndrome, gen-
eralised lymphadenopathy and dermatitis were predictive
of acute HIV infection [14]. Richardson et al performed
as i m i l a rs t u d yi nK e n y aw h e r e4 0( 7 1 % )o fa c u t e l y
infected infants were below 2 months of age in a cohort
of 189 infants. Acute infection was associated with
lymphadenopathy in ≥ 2 sites and upper respiratory
tract infection [15].
In a larger study from the pre-VTP era of infants born
to HIV-infected women, the Zimbabwe Vitamin A for
Mothers and Babies (ZVITAMBO) group evaluated
WHO, South African, and Zimbabwean algorithms for
HIV diagnosis in 6-week-old infants [9]. In this study,
52% of HIV-infected infants had a weight for age < 50
th
centile (Z score ≤ 0), and by focussing on this group,
the author’s developed diagnostic algorithms based on
clinical signs with relatively high yield. However, by
focussing only on HIV-exposed infants with weight-for-
age below the median, sensitivity of their clinical algo-
rithm for HIV diagnosis was 65%. When combined with
Table 4 Receiver Operating Characteristic (ROC) curves of combinations of clinical findings with the greatest area
under the curve (AUC), and sensitivity and specificity of various cut-off numbers of findings in predicting HIV-
infection among exposed infants.
One of a combination of oral thrush, any lymphadenopathy, hepatomegaly,
splenomegaly, plus:
ROC
AUC
Findings
present
Sensitivity
(%)
Specificity
(%)
A: weight < 15th centile, diaper dermatitis 0.754 1 77.9 61.2
2 47.7 88.0
3 25.2 98.4
B: weight < 50th centile, diaper dermatitis 0.717 1 88.9 29.6
2 48 90.4
3 20.6 99.2
C: weight < 3rd centile, reflux 0.744 1 63.8 80
2 31.4 97.6
3 12.5 100
One of a combination of oral thrush, diaper dermatitis, plus: ROC
AUC
Findings
present
Sensitivity
(%)
Specificity
(%)
D: weight < 3
rd centile 0.682 1 60.7 72
2 28.3 92.8
3 4.8 100
E: weight < 50
th centile 0.666 1 84.7 30.4
2 46.8 82.4
Table 3 Sensitivity and specificity of select clinical findings and events for distinguishing HIV-infected from exposed
uninfected infants
All exposed infants
Characteristic Sensitivity (95%CI) Specificity (95%CI) + LR
General LAD 14.6 (11.8-17.9) 97.6 (93.1-99.5) 6.1
Any LAD 24.4 (20.9-28.3) 95.2 (89.8-98.2) 4.8
Hepatomegaly 13.0 (10.2-16.1) 99.2 (95.6-100) 13
Splenomegaly 5.6 (3.8-7.8) 100 n/a
Oral thrush 30.2 (26.3-34.2) 89.6 (82.8-94.3) 164
Diaper rash 35.7 (31.1-40.5) 81.6 (12-26.3) 1.9
Reflux 2.8 (1.6-2.5) 100 n/a
Weight < 3
rd 14.6 (11.7-17.9) 93.6 (87.8-97.2) 2.3
Weight < 15
th 30.7 (26.9-34.8) 81.6 (73.7-87.9) 1.7
WAZ - weight-for-age score. CI - confidence interval.
+LR - positive likelihood ratio. n/a - not applicable.
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Page 5 of 7≥ two other physical signs (e.g. pneumonia, ear dis-
charge, treatment for TB, oral candidiasis), the sensitiv-
ity decreased to 20% but the specificity increased to
94%. Our algorithm including weight < 50
th centile
(algorithm B; table 3) but with different findings
improved sensitivity to 86% in this age group. Addition-
a l l y ,as i m p l i f i e da l g o r i t h mt h a ti n c l u d e dw e i g h t<5 0
th
maintained high sensitivity of 85%. However, algorithms
of this sort exclude the high proportion of HIV-infected
infants with weight above 50
th centile.
The ZVITAMBO approach [9] of focusing where yield
for subsequent DNA PCR testing may be highest
appears useful in settings with severe resource limita-
tions [16]. South Africa is a mid-income country that
can afford HIV-1 diagnostic PCRs on all HIV-exposed
infants. Therefore, although limiting tests to infants
below the 50
th centile may reduce costs, the number of
infants missed will be unacceptably high. Consequently,
an algorithm with higher sensitivity would be useful.
Additionally, in settings where PCR is unavailable or
turnaround time for results unacceptable, an algorithm
with high sensitivity may be preferred as a strategy for
ART initiation to prevent the early infant mortality asso-
ciated with HIV infection. Therefore using algorithm B,
m a yb ep r e f e r a b l ei nt h e s es e t t i n g s .T h ea d v a n t a g eo f
algorithms such as ours is that programs could adapt
the cut-off to suit their needs.
To our knowledge, ours is the first study to investigate
diagnostic algorithms of predominantly formula fed
infants in the VTP era. Our algorithms have the highest
sensitivity for HIV identification of all those previously
published, particularly in this age group.
The majority of other algorithms and guidelines to
identify HIV-infected children have not included infants
below two months of age [10-12]. Jones et al found a
sensitivity of 17% when applying the Integrated Manage-
ment of Childhood Illness (IMCI) algorithms for pre-
dicting pediatric HIV infection to a cohort of 301 HIV-
exposed infants in VTP programs, of whom 26 (8.7%)
were shown to be HIV-infected by HIV DNA PCR [10].
However, using clinical signs similar to those selected in
our study (hepatosplenomegaly, recurrent infections,
failure to thrive, and candidiasis) and where doctors
evaluating the infants were unaware of infection status,
the sensitivity for HIV infection increased to 56% at 6
weeks of age [10].
As expected, increasing the number of positive signs
reduces sensitivity but increases specificity. Reflux
occurred at low frequency (3.4%) but appeared very spe-
cific, albeit difficult to define. Of note, 11 (73%) of the
15 infants with reflux also had oral thrush, which could
have aggravated or caused the symptom; swallowing
incoordination, an early sign of encephalopathy, could
also have contributed. That oral thrush and low weight
for age were so highly specific in this population sug-
gests that these findings cannot only be attributed to
formula feeding or co-morbidities such as malnutrition
and TB.
A limitation of our study is that clinician’s knowledge
of the infants’ HIV status may have influenced the find-
ing and reporting of clinical findings. On the other
hand, HIV-infected infants eligible for CHER were
selected for lack of severe clinical disease [4] and doc-
tors trained for the study evaluated all infants. Our
results require validation in other settings, for example,
where malaria and breastfeeding are prevalent, and in
VTP programs with larger numbers of HIV-exposed
uninfected infants and with lower HIV prevalence. Our
study included a large group of HIV-infected infants
(77%) and a smaller number of HIV-exposed infants, all
below 10 weeks of age, in contrast to all of the other
studies. Also, as mentioned, infants with severe clinical
disease, where the diagnosis may be more obvious, were
also excluded. In settings where this algorithm would be
useful, the prevalence of HIV-infection amongst exposed
infants would be lower, and thus affect the positive and
negative predictive values of the algorithm. In addition,
due to selection methods, most HIV-infected infants
included in this analysis were relatively well, with a
median CD4 count of 34%. The algorithm may perform
better in a general population of HIV-infected infants.
Additionally, only 12% of this cohort was breastfeeding.
In conclusion, a combination of clinical findings in
infants below 10 weeks of age may be useful for predict-
ing HIV infection and prioritising care. There is urgent
need to validate these findings in other settings and to
determine their relevance in diverse settings.
Conclusion
A combination of physical findings is helpful in identify-
ing infants most likely to be HIV-infected. This may
inform management algorithms and provide guidance
for focused laboratory testing or antiretroviral initiation
in some settings, and should be further validated in
these settings and elsewhere.
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